Planning and management to control and eliminate HTLV-1 infection in Iran.

ATL HAM/TSP HTLV-1 Prevention Treatments

Journal

Iranian journal of basic medical sciences
ISSN: 2008-3866
Titre abrégé: Iran J Basic Med Sci
Pays: Iran
ID NLM: 101517966

Informations de publication

Date de publication:
Mar 2021
Historique:
entrez: 17 5 2021
pubmed: 18 5 2021
medline: 18 5 2021
Statut: ppublish

Résumé

Prevention and treatment of the Human T-cell leukemia virus, type 1 (HTLV-1) which was discovered nearly 40 years ago, still remain challenging. The reported high prevalence of HTLV-1 in some countries around the world triggered an open letter to the World Health Organization (WHO), urging action against HTLV-1 infection in 2018. This highlights the importance of virus elimination strategies to eradicate HTLV-1 infection. In Iran, we have documented our experiences with the virus in order to achieve and promote the possible ways to manage, control, and eliminate HTLV-1. Although there has been considerable progress apropos of HTLV-1, a series of additional challenges need to be tackled to control HTLV-1 infection in Iran.

Identifiants

pubmed: 33995937
doi: 10.22038/ijbms.2021.50803.11562
pmc: PMC8087857
doi:

Types de publication

Journal Article

Langues

eng

Pagination

264-266

Références

Blood. 2009 Jun 25;113(26):6528-32
pubmed: 19411628
Lancet Infect Dis. 2019 Jan;19(1):15-16
pubmed: 30587282
PLoS Negl Trop Dis. 2012;6(6):e1675
pubmed: 22720101
J Neuroimmunol. 2012 Sep 15;250(1-2):87-93
pubmed: 22727800
Iran J Basic Med Sci. 2013 Mar;16(3):196-201
pubmed: 24470861
Iran J Basic Med Sci. 2013 Mar;16(3):225-8
pubmed: 24470867
Lancet. 2018 May 12;391(10133):1893-1894
pubmed: 29781438
J Clin Virol. 2011 Nov;52(3):172-6
pubmed: 21840754
BMJ Open. 2016 Apr 26;6(4):e010654
pubmed: 27118288
Adv Ther. 2018 Feb;35(2):135-152
pubmed: 29411267
Virol J. 2017 Jan 30;14(1):14
pubmed: 28137274
AIDS Res Hum Retroviruses. 2012 Sep;28(9):1095-1101
pubmed: 22229796

Auteurs

Reza Boostani (R)

Department of Neurology, Mashhad University of Medical Sciences, Mashhad, Iran.

Nasim Lotfinejad (N)

Department of Research, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

Fariba Zemorshidi (F)

Department of Neurology, Mashhad University of Medical Sciences, Mashhad, Iran.

Zohreh Vahidi (Z)

Immunology Research Centre, Inflammation and Inflammatory Diseases Division, Mashhad University of Medical Sciences, Mashhad, Iran.

Seyed Abdolrahim Rezaee (SA)

Immunology Research Centre, Inflammation and Inflammatory Diseases Division, Mashhad University of Medical Sciences, Mashhad, Iran.

Reza Farid (R)

Allergy Research Centre, Mashhad University of Medical Sciences, Mashhad, Iran.

Houshang Rafatpanah (H)

Immunology Research Centre, Inflammation and Inflammatory Diseases Division, Mashhad University of Medical Sciences, Mashhad, Iran.

Classifications MeSH